title: Corticosteroids in the treatment of alcohol-induced rhabdomyolysis.
abstract: Rhabdomyolysis is a common condition with potentially devastating complications, including acute renal failure, arrhythmias, and death. The standard of care is to use supportive measures such as aggressive fluid repletion to prevent kidney injury and attenuate clinical symptoms. Besides fluid management, few therapeutic options are available for the treatment of acute rhabdomyolysis. As a result, acute and refractory cases remain difficult to manage. We report a case of alcohol-induced rhabdomyolysis that responded dramatically to high-dose corticosteroids. A 55-year-old man presented to the emergency department for evaluation of diffuse muscle pain, weakness, and darkening urine. On admission, his creatine kinase (CK) level was 50,022 U/L. Despite aggressive fluid repletion, his CK level continued to increase, peaking at 401,280 U/L with a concomitant increase in muscle pain and urine darkening. On administration of high-dose corticosteroids, clinical symptoms and CK levels improved dramatically, and the patient was discharged 36 hours later with complete resolution of muscle pain and weakness. Given their low toxicity profile, short-term high-dose corticosteroids may be a valid treatment option for recurrent rhabdomyolysis unresponsive to fluid repletion.
authors.affiliation: Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA, USA.
authors.forename: James W
authors.initials: JW
authors.lastname: Antoon
authors.forename: Chayan
authors.initials: C
authors.lastname: Chakraborti
mesh_terms: D000428:Alcohol Drinking / Q000009:adverse effects*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002492:Central Nervous System Depressants / Q000009:adverse effects; D003402:Creatine Kinase / Q000097:blood; D000431:Ethanol / Q000009:adverse effects*; D005440:Fluid Therapy; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000187:drug effects; D012008:Recurrence; D012206:Rhabdomyolysis / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000628:therapy
chemical_list: D000893:Anti-Inflammatory Agents; D002492:Central Nervous System Depressants; D005938:Glucocorticoids; D000431:Ethanol; D003402:Creatine Kinase; D008775:Methylprednisolone